James Willson, MD

Associate Dean, Oncology Programs
Professor
Endowed Title: Lisa K. Simmons Distinguished Chair in Comprehensive Oncology
Simmons Comprehensive Cancer Center, Internal Medicine

Contact Information

UT Southwestern Medical Center
5323 Harry Hines Boulevard
Dallas, Texas 75390

Office Phone: 214-648-4190
Office Fax: 214-648-7084

james.willson@utsouthwestern.edu

To make an appointment, call 214-645-8300.

Biography

Dr. James Willson was named Director of the Simmons Comprehensive Cancer Center in the fall of 2004 following a 10-year tenure as Director of the Case Comprehensive Cancer Center and University Hospitals Ireland Cancer Center at Case Western Reserve University and University Hospitals of Cleveland. He also serves as Associate Dean for Cancer Programs at UT Southwestern Medical Center. Dr. Willson received his M.D. from the University of Alabama in 1976, his training in medicine on the Osler Medical Service at Johns Hopkins Hospital, 1976-1978, 1980, and in medical oncology in the Medicine Branch of the NCI, 1978-80. Prior to his move to UT Southwestern, he was a member of the Wisconsin Comprehensive Cancer Center, 1981-87; and the Case Comprehensive Cancer Center, 1987-2004. Dr. Willson’s research interest focuses on colon cancer treatment. His extramural service includes past service on the Board of Scientific Counselors, National Cancer Institute, as a Member of the Experimental Therapeutics Study Section, National Institutes of Health and as Chair of Subcommittee A Cancer Centers, National Cancer Institute Initial Review Group. Currently he serves on the Board of Scientific Advisors for the National Cancer Institute.

Education

Chief ResidentJohns Hopkins Hospital, Internal Medicine (1981)
ResidencyCancer Prevention Fellowship Program, Internal Medicine (1980)
ResidencyJohns Hopkins Hospital, Internal Medicine (1978)
InternshipJohns Hopkins Hospital, Internal Medicine (1977)
Medical SchoolUniversity of Alabama School of Medicine (1976)

Research Interests

Colon cancer
Targeted cancer therapeutics

Publications

Featured
Inactivation of the type II TGF-Β receptor in RER colon cancers with microsatellite instability.

Markowitz S, Wang J, Myeroff l, Parons R, Sun LZ, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B, Brattain M, Willson JKV , Science , Spring 1995; (268):1336-8

Featured
Contextual effects of TGF-Β on the tumorigenicity of human colon carcinoma cells.

Ye SC, Foster JM, Li WH, Liang JR, Zborowska E, Venkateswarlu S, Gong JG, Brattain MG, Willson JKV , Cancer Research , September 1999; (59):4725-31

Featured
Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation.

Dowlati A, Haaga J, Remick SC, Spiro TP, Gerson SL, Liu L, Berger SJ, Berger NA, Willson JKV , Clinical Cancer Research , October 2001; (7):2971-6

Featured
O6-Benzylguanine: A clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair.

Spiro TP, Gerson SL, Liu L, Majka S, Haaga J, Hoppel CL, Ingalls ST, Willson JKV , Cancer Research , May 1999; (59):2402-10

Featured
High frequency of mutations of the PIK3CA gene in human cancers.

Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JKV, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE , Science , April 2004; (304/5670):554

Mutational analysis of the tyrosine phosphatome in colorectal cancers.

Wang Z, Shen D, Parsons DW, Bardelli A, Sager J, Szabo S, Ptak J, Silliman N, Peters BA, van der Heijden MS, Parmigiani G, Yan H, Wang TL, Riggins G, Powell SM, Willson JK, Markowitz S, Kinzler KW, Wogelstein B, Velculescu VE , Science , May 2004; (304/5674):1164-6

Mutational analysis of the tyrosine kinome in colorectal cancers

Bardelli A, Parsons DW, Silliman N, Ptak J, Szabo S, Saha S, Markowitz S, Willson JK, Parmigiani G, Kinzler KW, Wogelstein B, Velculescu VE , Science , May 2003; (300/5621):949

15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-Β-induced suppressor of human gastrointestinal cancers.

Yan M, Rerko RM, Platzer P, Dawson D, Willis J, Tong M, Lawrence E, Lutterbaugh J, Lu S, Willson JK, Lui G, Hensold J, Tai HH, Wilson K, Markowitz SD , Proc Natl Acad Sci USA , December 2004; (101/50):17468-73

ErbB family targeting.

Black JD, Brattain MG, Krishnamurthi SA, Dawson DM, Willson JKV , Curr Opin Investig Drugs , December 2003; (4(12)):1451-4

High frequency of mutations of the PIK3CA gene in human cancers.

Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JKV, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE , Science , April 2004; (304/5670):554

Honors/Awards

Lisa K. Simmons Distinguished Chair in Comprehensive Oncology

UT Southwestern medical Center at Dallas (2004)

Circle of Life Award

American Hospital Association for Project Safe Conduct (2002)

John Peter Minton Hero of Hope Research Medal of Honor

American Cancer Society Ohio Division (2002)